Background: Higher breast cancer mortality rates for AfricanAmerican than non-Hispanic White women are well documented; however, it remains uncertain if this disparity occurs in disease subgroups defined by tumor molecular markers and stage at diagnosis. We examined racial differences in outcome according to subtype and stage in a diverse, population-based series of 103,498 patients.
Introduction
Although breast cancer mortality rates have declined in the United States over the past few decades (1), African-American women experience substantially higher breast cancer mortality than non-Hispanic white (White) women (2, 3) . The mortality disparity is especially noteworthy in light of the lower incidence rate of breast cancer among African-American than White women (4, 5) .
This racial/ethnic disparity in breast cancer outcomes has been well studied and prior studies have set forth biologic and nonbiologic explanations for the mortality difference (6) (7) (8) (9) . AfricanAmerican women are more likely to be diagnosed at a later stage of breast cancer than Whites, which may be due to factors such as limited primary care (10) or longer follow-up time after an abnormal or inconclusive screening mammogram (11, 12) . Poorer survival also may be influenced by patient social context disproportionately affecting African-American women, specifically socioeconomic deprivation at the individual or neighborhood levels, and social injustice (13, 14) . However, there is also evidence that, relative to White women, breast cancer among AfricanAmerican women may be biologically more aggressive and more likely to express molecular markers [i.e., estrogen receptor (ER) and progesterone receptor (PR) (together referred to as hormone receptor (HR)), and human epidermal growth factor receptor 2 (HER2)] associated with worse outcomes (7, (15) (16) (17) . In particular, African-American women are more likely than White women to be diagnosed with triple-negative breast cancer, which, because of its lack of expression for the three molecular markers, does not currently have targeted treatment options (7, (15) (16) (17) . A few studies have measured the contribution of molecular subtype to racial/ethnic disparities in breast cancer survival (18) (19) (20) , but the findings were inconsistent when comparing survival in AfricanAmerican patients with Whites. One study found that mortality risk difference between African-American and White women occurs only among older women diagnosed with luminal A/p53-but not with triple-negative breast cancer (18) , whereas another two studies suggested higher overall mortality (19) and breast cancer-specific (BCS) mortality (20) in African-American than White patients with the triple-negative subtype. To date, there have been no datasets large enough to examine racial/ethnic mortality disparities by tumor molecular subtypes and stage at diagnosis, the two important prognostic determinants of survival, to further isolate the subgroups with the worst disparities.
We took advantage of the California Cancer Registry, for which breast cancers defined by ER, PR, and HER2 status are reported for a particularly large and racially/ethnically diverse population to study overall and BCS mortality among White and African-American women diagnosed with invasive breast cancer during the period 2005-2012. We assessed whether mortality differences persisted across molecular subtype and stage at diagnosis, defined jointly. We also assessed the contributions of clinical and demographic characteristics, including first course of treatment, neighborhood socioeconomic status (SES), and health insurance status, to racial/ethnic mortality differences.
Materials and Methods

Study population
We (21, 22) . Patient residential address at diagnosis was geocoded to a census block group. In our study, 1.6% of all cases could not be geocoded due to incomplete address. Each patient was assigned a neighborhood SES quintile, based on the distribution of SES across census block groups in California.
Breast cancer subtype definition
The CCR has collected information on the expression of ER and PR since 1990 and of HER2 since 1999 (23 (7, 17, (23) (24) (25) . Of the 103,498 cancers, 14,287 (13.8%) did not have information needed to assign to one of these subtypes, including 8,597 cancers (8.3%) for whom only HER2 status was unknown, 608 cancers (0.6%) for whom only HR status was unknown, and 5,690 cancers (5.5%) for whom both HR and HER2 status were unknown. Cancers for which subtype was missing did not differ statistically significantly with respect to patient race/ethnicity from those for which subtype was known.
Statistical analysis
The Mantel-Haenszel x 2 test was used to compute P values for differences in distribution of patient and clinical characteristics between White and African-American patients. Cox proportional hazards regression was used to estimate relative hazard (RH) and corresponding associated 95% confidence intervals (CI) with independent variables added in turn to understand their individual effects. The Kaplan-Meier method and the log-rank test were used to show and test differences in overall survival for patients diagnosed at each stage by breast cancer subtype.
For deceased patients, survival time was measured in days from the date of diagnosis to the date of death from breast cancer. Patients who died from other causes were censored at the time of death. Patients alive at the study end date (12/31/2012) were censored at this time or at the date of last follow-up (i.e., last known contact). The proportional hazards assumption was examined by statistical testing of the correlation between weighted Schoenfeld residuals and logarithmically transformed survival time. No violations of the assumption were observed. Given that proportional hazards varied by stage at diagnosis (AJCC stage I-IV and unknown), it was included as a stratifying variable in all Cox regression models, allowing the baseline hazard to vary by stage. All models were adjusted for clustering by block group. Ninetyeight percent of censored patients had a follow-up date within 2 years of the study end date; the proportion of patients without recent follow-up information did not differ by race/ethnicity nor by neighborhood SES.
Cells with fewer than five cases are not shown for privacy purposes. All statistical tests were carried out using SAS software version 9.3 (SAS Institute). All P values reported were two-sided, and those that were <0.05 were considered to be statistically significant. deviation) age at diagnosis was higher for White (62.3 AE 13.6 years) than African-American women (58.8 AE 13.7 years). Compared with whites, African-American patients were more likely to be diagnosed at a younger age, to be unmarried, to live in lower SES neighborhoods, to be diagnosed at a more advanced stage, to have larger tumors, and to have public insurance or no insurance (all P < 0.05, Table 1 ). Approximately 20% of African-American, whereas only 10% white patients were diagnosed with triplenegative breast cancer.
After a mean follow-up time of 3.5 (AE2.3) years, AfricanAmerican patients had an 18% overall increased risk of death from breast cancer (RH, 1.18; 95% CI, 1.10-1.27) compared with White patients after including stage as a stratifying variable and adjusting for molecular subtype, age at diagnosis, marital status, tumor characteristics, treatment modalities, neighborhood SES, and insurance status (data not shown on table). This deficit in BCS survival was observed across all molecular subtypes (all P log-rank < 0.01, Fig. 1 
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À breast cancers at stages II and III, for which breast cancers respond favorably to antiendocrine therapy or trastuzumab therapy (37) . This underscores the central role of treatment in the Black/White disparity in breast cancer, even though no race/ethnicity Research.
on June 20, 2017. © 2015 American Association for Cancer cebp.aacrjournals.org Downloaded from differences in adjuvant hormone therapy use were identified in two recent studies (38, 39) . Unfortunately, information on endocrine therapies is under-captured in cancer registry data, and specific information regarding receipt of trastuzumab is not reported. Cancer registry first course of treatment data do not include information on specific components of chemotherapy, nor aspects such as timing, dosage, completion of regimen, guideline adherence, or details on the specific types of surgery, radiation, endocrine, or chemotherapy agents.
Other nonbiologic factors and factors independent of stage at presentation, such as residual treatment/healthcare differences due to social and health system factors, may also explain a significant portion of the mortality disparity. Racial/ethnic differences in receipt of treatment may exist even among those with insurance, and may be attributable to patient (e.g., comorbidities) factors, healthcare system factors, or differences in tumor biology or response to treatments. African-American women are less likely to receive adequately dosed, timely, and appropriate administration of chemotherapy (40) (41) (42) (43) , and adjuvant radiotherapy after breast-conserving surgery (44, 45) . Historically underserved populations, including African-Americans, generally benefit less from medical advances (46) . It remains to be seen whether the shift toward more personalized treatment options based in gene expression testing/profiling, including evolving HER2-directed and antiendocrine therapies, will result in more pronounced mortality disparities for African-Americans. Deficiencies in treatment and care among African-American breast cancer patients may result from a number of contributing causes. Although health insurance status is the most referenced and an important barrier (47) (48) (49) , a number of additional factors, such as out-of-pocket financial hardship caused by cancer care (50), need for time taken from work (51), and problems with travel (52, 53) , may also disproportionally affect the cancer treatment and care of African-American women. In addition, the nuanced role of patient-physician communication, which is understood to affect physicians' care recommendations and patients' compliance with treatment (54) , is also relevant, as African-American patients have been reported to have more misunderstandings about treatment (55, 56) and lower satisfaction or trust of the health care system (57) . Thus, although overall, the quality of breast cancer care is improving and mortality rates is declining, disparities still remain, such that African-Americans may still receive insufficient, poorer-quality, and diminished access to care as compared with Whites (10).
Our study has the strength of being population-based with large numbers of African-American and White cases to enable examination of breast cancer mortality across combinations of subtypes and stage. Although we did adjust outcomes according to available demographic and clinical characteristics, we lacked clinical information on detailed regimens for treatment and treatments received after the first course. Another limitation is our inability to control for individual-level measures of SES, like level of education or income. Although neighborhood and individual SES are strongly correlated, neighborhood SES under-estimates associations observed with individual-level markers (58) . Furthermore, our mean follow-up was 3.5 years (and our maximum 8 years), because of the recency of HER2 data availability; thus, our results cannot speak to longer-term survival. However, it has been reported that the disparity in breast cancer mortality between African-Americans and nonHispanic Whites is more pronounced during the first few years 
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